Correction to: Oncogene (2015) 34, 2505−2515; doi:10.1038/onc.2014.184; published online 7 July 2014
Since the publication of the above article, the authors have noticed that the PUMA immunostainings in the ‘A549 (NC) treated with cisplatin’ panels in Figure 4c was incorrect. The authors acknowledged this was the result of administrative error and have provided the correct images for the affected panels. A corrected version of Figure 4c is below. The results and conclusions put forth in this article remain unchanged.
The authors would like to apologise for this error and the inconvenience this may have caused.
Additional information
The online version of the original article can be found at 10.1038/onc.2014.184
Rights and permissions
About this article
Cite this article
Wu, DW., Lee, MC., Hsu, NY. et al. Erratum: FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction. Oncogene 36, 5439 (2017). https://doi.org/10.1038/onc.2017.249
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2017.249
This article is cited by
-
Non-redundant functions of EMT transcription factors
Nature Cell Biology (2019)
-
IL-6-driven FasL promotes NF-κBp65/PUMA-mediated apoptosis in portal hypertensive gastropathy
Cell Death & Disease (2019)
